Stay updated on Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial

Sign up to get notified when there's something new on the Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.2 to v3.8.0 while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-03T23:57:45.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    A site-wide NIH notice about updated terminology appears above the 403 error page. The footer revision changes from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-20T23:58:07.000Z thumbnail image
  4. Check
    30 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer now displays revision v3.7.1 instead of v3.7.0. The page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-07T00:11:48.000Z thumbnail image
  5. Check
    44 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error instead of the study record content, indicating access is blocked. This change suggests that the requested record cannot be accessed at the moment, impacting the ability to view study details.
    Difference
    20%
    Check dated 2026-09-23T00:27:40.000Z thumbnail image
  6. Check
    51 days ago
    Change Detected
    Summary
    Revision label on the page changed from v3.6.6 to v3.7.0, indicating an update to the page’s underlying system or content. This is a minor maintenance update rather than a change to the study information itself.
    Difference
    0.1%
    Check dated 2026-09-15T23:25:43.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    Revision: v3.6.6 is now shown on the page, replacing the previous v3.6.5. This indicates a minor update to the page's revision metadata rather than a substantive change to the study content.
    Difference
    0.1%
    Check dated 2026-09-01T18:26:00.000Z thumbnail image

Stay in the know with updates to Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial page.